subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast \> 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr \< 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. 11. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast \> 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr \< 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. 11. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. admission into the intensive care unit (icu) at screening and baseline. clinically active hepatitis. alt or ast > 3 times the upper limit of normal. need for invasive or non-invasive ventilation at screening and baseline. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. known allergy to disulfiram. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. participation in any other interventional trial within 30 days prior to enrollment. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. admission into the intensive care unit (icu) at screening and baseline. clinically active hepatitis. alt or ast > 3 times the upper limit of normal. need for invasive or non-invasive ventilation at screening and baseline. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. known allergy to disulfiram. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. participation in any other interventional trial within 30 days prior to enrollment. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast > 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. 11. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast > 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. 11. fully vaccinated for covid-19 (number of doses as per manufacturer recommendation.

subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast > 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study.

subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. admission into the intensive care unit (icu) at screening and baseline. 2. clinically active hepatitis. 3. alt or ast > 3 times the upper limit of normal. 4. need for invasive or non-invasive ventilation at screening and baseline. 5. stage 4 severe chronic kidney disease or requiring dialysis or estimated gfr < 30. 6. known allergy to disulfiram. 7. treatment with any of the medications listed below within 7 days prior to the baseline visit 1: amprenavir, dronabinol, hydantoins, metronidazole, ritonavir, benznidazole, dyphylline, idelalisib, naltrexone, sertraline, chloral hydrate, ethanol, immuno-modulatory drugs, paclitaxel, tinidazole, cocaine, ethotoin, ixabepilone, phenytoin, tipranavir, cyclosporine, fosphenytoin, lithium, pimozide, tranylcypromine, dasabuvir, guaifenesin, mesoridazine, pirfenidone. 8. participation in any other interventional trial within 30 days prior to enrollment. 9. active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by nccn criteria). 10. any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study.